Literature DB >> 25183047

Bevacizumab in advanced cervical cancer.

P J Vlachostergios1, C N Papandreou.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25183047     DOI: 10.1007/s12094-014-1205-7

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


× No keyword cloud information.
  5 in total

1.  RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma.

Authors:  Tracey Schefter; Kathryn Winter; Janice S Kwon; Kelly Stuhr; Khalid Balaraj; Brian Patrick Yaremko; William Small; William Sause; David Gaffney
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-01-01       Impact factor: 7.038

2.  ACR Appropriateness Criteria® role of adjuvant therapy in the management of early stage cervical cancer.

Authors:  Aaron H Wolfson; Mahesh A Varia; David Moore; Gautam G Rao; David K Gaffney; Beth A Erickson-Wittmann; Anuja Jhingran; Nina A Mayr; Ajmel A Puthawala; William Small; Catheryn M Yashar; William Yuh; Higinia Rosa Cardenes
Journal:  Gynecol Oncol       Date:  2011-12-07       Impact factor: 5.482

Review 3.  Tissue biomarkers as prognostic variables of cervical cancer.

Authors:  Angiolo Gadducci; Maria Elena Guerrieri; Carlo Greco
Journal:  Crit Rev Oncol Hematol       Date:  2012-09-30       Impact factor: 6.312

4.  Improved survival with bevacizumab in advanced cervical cancer.

Authors:  Krishnansu S Tewari; Michael W Sill; Harry J Long; Richard T Penson; Helen Huang; Lois M Ramondetta; Lisa M Landrum; Ana Oaknin; Thomas J Reid; Mario M Leitao; Helen E Michael; Bradley J Monk
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

5.  Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer.

Authors:  Israel Zighelboim; Jason D Wright; Feng Gao; Ashley S Case; L Stewart Massad; David G Mutch; Matthew A Powell; Premal H Thaker; Eric L Eisenhauer; David E Cohn; Fidel A Valea; Angeles Alvarez Secord; Lynne T Lippmann; Farrokh Dehdashti; Janet S Rader
Journal:  Gynecol Oncol       Date:  2013-04-13       Impact factor: 5.482

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.